Introducing BetterLix, A New AI-Powered App to Support a Liver-Healthy Lifestyle

Using a proprietary AI-algorithm, BetterLix helps liver patients to make liver-healthy lifestyle choices every day.

BetterLix

Amsety, a liver health solutions company announced the release of its new AI-powered app – BetterLix, a smart digital liver health coach. Developed by liver health experts and mathematicians, BetterLix utilizes the power of AI and the latest research on liver health to create personalized daily liver health plans. These plans encompass tailored lifestyle and diet recommendations to meet individual health needs. By providing guidance on liver health, BetterLix is designed to tackle the root causes of the liver disease epidemic: poor nutrition and unhealthy lifestyle.

Liver Disease in the U.S.

The launch of BetterLix comes at a critical time for liver patients. In last few decades, fatty liver disease has become an epidemic in the U.S. with now over 100 million Americans being affected by liver conditions, mostly fatty liver disease or also called metabolic dysfunction-associated fatty liver disease (MAFLD). Poor nutrition and a sedentary lifestyle are considered the major risk factors for developing fatty liver disease. Implementing lifestyle and diet changes, however, can prevent or even reverse MAFLD. With limited pharmacological treatments, the role of lifestyle and diet modifications is critical.

Despite an alarmingly high prevalence of fatty liver disease in the U.S., the availability of guidance on a liver-healthy lifestyle is insufficient. In Amsety´s survey conducted at The AASLD Liver Meeting in 2023, 72% liver health experts believe that “better nutrition guidelines” is the number one priority in lifestyle interventions. 92% of liver health experts also suggest the use of a digital tool that provides guidance on a liver-healthy lifestyle and nutrition to liver patients.

How does BetterLix work?

It generates easy and scientifically backed tasks that fit into daily routines, assisting liver patients in establishing a sustainable and long-term liver-healthy lifestyle. The tasks are tailored to the individual preferences and profile of each patient. The App makes it easy to follow a healthy lifestyle by providing instant feedback and progress tracking. BetterLix utilizes a comprehensive approach to liver disease and offers guidance on such areas as food and nutrition, exercise, sleep, workplace, mental health, and hydration.

For healthcare providers, BetterLix opens more efficient ways to reach and connect with liver patients.

SourceAmsety

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version